McGourty J C, Silas J H, Solomon S A
Postgrad Med J. 1985 Mar;61(713):229-32. doi: 10.1136/pgmj.61.713.229.
We have used a combination of a beta-blocker and verapamil to treat 42 consecutive patients with angina resistant to either agent alone. Patients with heart failure, heart block or uncontrolled hypertension were excluded. The mean duration of follow-up was 6.5 months. Thirty-six patients (81%) reported an improvement and the number of angina attacks was reduced from 17/week to 5/week. Side effects necessitated withdrawal of one or both drugs in 6 patients, 2 of whom developed bradyarrhythmias not solely related to drug treatment. The most common complication was mild left ventricular failure (6) treated by reducing or stopping the beta-blocker. The data suggest that the combination of verapamil and a beta-blocker may be used in a relatively unselected group of patients with difficult angina. However, as dosage adjustment and close observation may be necessary to minimise side effects, the use of this combination should be limited to hospital practice.
我们联合使用β受体阻滞剂和维拉帕米治疗了42例单独使用任何一种药物均耐药的心绞痛患者。排除了心力衰竭、心脏传导阻滞或未控制的高血压患者。平均随访时间为6.5个月。36例患者(81%)报告病情改善,心绞痛发作次数从每周17次减少至每周5次。6例患者因副作用需要停用一种或两种药物,其中2例出现的缓慢性心律失常并非完全与药物治疗有关。最常见的并发症是轻度左心室衰竭(6例),通过减少或停用β受体阻滞剂进行治疗。数据表明,维拉帕米和β受体阻滞剂联合使用可用于相对未经筛选的难治性心绞痛患者群体。然而,由于可能需要调整剂量并密切观察以尽量减少副作用,这种联合用药应仅限于医院临床应用。